Sponsor:
Dana-Farber Cancer Institute
Code:
NCT07710131
Conditions
PCNSL
Brain Tumor
Cognitive Dysfunction
IDH Mutation
Low-grade Glioma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Digital Cognitive Assessment (TestMyBrain and Mobile Toolbox)
Traditional Neuropsychological Testing
Quality of Life and Mood Questionnaires
Brain MRI (Standard of Care)
Brief summary:
Conditions
PCNSL
Brain Tumor
Cognitive Dysfunction
IDH Mutation
Low-grade Glioma
Study ID
NCT07710131
Start date
Sep 2, 2026
Status verified date
Nov, 2026
Completion date
Jan 1, 2029
Anticipated
Primary completion date
Jan 1, 2028
Anticipated
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
36 participants
Anticipated
Intervention Model
Single group
Primary purpose
Diagnostic
Arms
other: Digital Cognitive Assessment
Interventions
Digital Cognitive Assessment (TestMyBrain and Mobile Toolbox)
Traditional Neuropsychological Testing
Quality of Life and Mood Questionnaires
Brain MRI (Standard of Care)
Primary outcome measure
Central contacts
Locations
Dana-Farber Cancer Institute
Recruiting
Boston, Massachusetts, United States, 02215
Contacts
Andrea Saric-Hayes
andrea_saric-hayes@dfci.harvard.eduSponsor
Dana-Farber Cancer Institute
Last update posted
Nov 20, 2026
Last verified
Nov, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-21. This information was provided to ClinicalTrials.gov by Dana-Farber Cancer Institute on 2026-11-20. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.